Population Bio, Inc. a Precision Medicine Company
Population Bio, Inc. is a privately held precision medicine company that is empowering pharmaceutical companies to develop targeted therapies and companion diagnostics faster and more cost effectively. We are accelerating the delivery of precision medicine diagnostic and therapeutic products to enable safe, low-cost, and effective healthcare for patients. Operating at the hub of worldwide Parkinson`s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson`s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson`s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
Welcome
Population Bio’s mission is to make drugs safer and more effective. We accelerate the delivery of precision medicine products to patients by discovering disease-relevant genetic biomarkers that enable:
- Companion diagnostic test development to identify patients at risk of a serious adverse event (SAE) for currently marketed drugs.
- Drug repurposing (repositioning) for new indications based on genetic subtypes of common diseases.
- Drug rescue of promising therapies that fail in clinical trials for safety or efficacy.
- Disease-modifying drug development for novel targets based on genetic discoveries (causal or protective variants).
Population Bio’s CNV Beacon® platform reduces the genome search space for faster, lower cost discovery of disease-relevant genes and variants.
Company Overview
Our patented genetic discovery method is currently used in multiple collaborations and partnerships to:
- Define new classes of rare diseases by revealing multiple subtypes of common, complex diseases (e.g., Autism, Parkinson’s, Alzheimer’s, Endometriosis, Peanut Allergy, etc.).
- Genetically stratify drug responders vs. non-responders to improve clinical trials.
- Identify the genetic basis of serious adverse events to facilitate development of companion tests that improve the safety of approved drugs.
- Reveal protective variants that enable development of blockbuster drugs for treating a common disease in a large number of people (irrespective of underlying cause).